U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8N4
Molecular Weight 160.1762
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDRALAZINE

SMILES

c1ccc2c(c1)cn[nH]c2=NN

InChI

InChIKey=RPTUSVTUFVMDQK-UHFFFAOYSA-N
InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C8H8N4
Molecular Weight 160.1762
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/hydralazine.html

Hydralazine is a direct-acting vasodilator that is used as an antihypertensive agent. Hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. Hydralazine is used for the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

CNS Activity

Curator's Comment:: some metabolites of hydralazine are known to cross the blood-brain barrier

Originator

Curator's Comment:: In 1951 the Hypertension Division at Washington University initiated the use of hydralazine

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
400.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Hydralazine Hydrochloride

Approved Use

Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.

Launch Date

4.78137614E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3 μM
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
407 μM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
HYDRALAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Sources:
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Disc. AE: Lethargy, Hypotension...
AEs leading to
discontinuation/dose reduction:
Lethargy
Hypotension
Tachycardia
Chest pain
Sources: Page: p.53, 54
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Disc. AE: Skin rash, Febrile reaction...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Febrile reaction (rare)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources: Page: p.2
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Disc. AE: Angina pectoris, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Angina pectoris
Myocardial infarction
Peripheral neuritis
Sources: Page: p.3
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Tachycardia Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
Chest pain Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Hypotension Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Lethargy Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Tachycardia Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Febrile reaction rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Skin rash rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Glomerulonephritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Systemic lupus erythematosus synd Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Angina pectoris Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Myocardial infarction Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Peripheral neuritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Glomerulonephritis Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Systemic lupus erythematosus synd Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >1000 uM]
no
unlikely
unlikely
unlikely
unlikely
yes [IC50 197 uM]
yes [Ki 83 uM]
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Clinical consequences of polymorphic acetylation of basic drugs.
1977 Sep
Immunological side-effects of antihypertensive drugs.
1979
Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.
1979 Apr
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
1985 Mar
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
1985 Sep 27
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug.
1985 Sep-Oct
Drug-associated glomerulopathies.
1986
Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
1986
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
1986
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
1986 Jun
Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.
1987 Apr
Isolated minimal change nephropathy associated with diclofenac.
1987 Jul 18
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
1987 May
Hydralazine-induced cholestatic jaundice following liver transplantation.
1989 Jan
Myocardial ischemia during isoflurane anesthesia: the effect of substituting halothane.
1989 Jun
Prevention of arterial disease in experimental renal hypertension.
1990 Apr
Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.
1990 Jan
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
1991 Aug 1
Renal arteriolar diameters in spontaneously hypertensive rats. Vascular cast study.
1991 Jul
Myocardial ischemia during vasodilator therapy in a canine model of pulmonary hypertension and coronary insufficiency.
1992 May
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
2001 Aug
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
2001 Aug
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
2001 May
Drugs for treatment of very high blood pressure during pregnancy.
2002
[Pulmonary hypertension and pregnancy].
2002 Feb
Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.
2004 Mar
Tight blood pressure control decreases apoptosis during renal damage.
2004 Mar
Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy.
2005 Apr 4
Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening.
2005 Jan 15
Synthesis and luminescence properties of lanthanide complexes incorporating a hydralazine-derived chromophore.
2005 Jan 7
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
2005 Jul 7
Epigenetics of cervical cancer. An overview and therapeutic perspectives.
2005 Oct 25
Hydralazine target: from blood vessels to the epigenome.
2006 Feb 28
Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: prevention by aldehyde scavengers.
2006 Mar 31
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
2007 Apr 3
A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial.
2007 Aug
The prince and the pauper. A tale of anticancer targeted agents.
2008 Oct 23
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
2008 Sep
Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart.
2009 Feb 14
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
2009 Jan
4-Hydrazino-2-(methyl-sulfan-yl)-pyrimidine.
2009 Jan 31
Hydralazine-induced cholestatic hepatitis.
2009 Jul-Aug
Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.
2009 Jun
D-penicillamine-induced autoimmunity: relationship to macrophage activation.
2009 Sep
Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury.
2010 Jan 29
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
2010 Sep
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties.
2011 Jun
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
2013 Feb 25
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be used intramuscularly or as a rapid intravenous bolus injection directly into the vein. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Initial dose: 10 mg orally 4 times a day for the first 2 to 4 days. Increase to 25 mg orally 4 times a day for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg orally 4 times a day.
Route of Administration: Oral
In Vitro Use Guide
Hydralazine (0.03-10 mmol.L(-1)) inhibited the activities of both PKA and PKG with IC50 of 1.2 and 2.5 mmol.L(-1), respectively
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:56:50 UTC 2021
Edited
by admin
on Sat Jun 26 03:56:50 UTC 2021
Record UNII
26NAK24LS8
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
HYDRALAZINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
1-HYDRAZINOPHTHALAZINE
Systematic Name English
HYDRALAZINE [WHO-DD]
Common Name English
HYDRALAZINE [MI]
Common Name English
HYDRALAZINE [INN]
Common Name English
NSC-126699
Code English
HYDRALAZINE [IARC]
Common Name English
HYDRALAZINE [VANDF]
Common Name English
PHTHALAZINE, 1-HYDRAZINO-
Systematic Name English
HIDRAL
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 334611
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
WHO-ATC C02DB02
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.3
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
FDA ORPHAN DRUG 166703
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
NDF-RT N0000175379
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
WHO-VATC QC02LG02
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
WHO-VATC QC02DB02
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
LIVERTOX 482
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
NCI_THESAURUS C270
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
NDF-RT N0000175564
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
WHO-ATC C02LG02
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
Code System Code Type Description
CAS
86-54-4
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
FDA UNII
26NAK24LS8
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
RXCUI
5470
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY RxNorm
IUPHAR
7326
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
LACTMED
Hydralazine
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
PUBCHEM
3637
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
DRUG BANK
DB01275
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
EVMPD
SUB08059MIG
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
EPA CompTox
86-54-4
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
ChEMBL
CHEMBL276832
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
WIKIPEDIA
HYDRALAZINE
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
INN
1
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-680-3
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
MERCK INDEX
M6072
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C62032
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
MESH
D006830
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
DRUG CENTRAL
1384
Created by admin on Sat Jun 26 03:56:50 UTC 2021 , Edited by admin on Sat Jun 26 03:56:50 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
INNOVATOR->PARENT
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Spontaneously cyclizes to the stable product 3-methyl-s-triazolo-[3,4-a]phthalazine (MTP).
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Acetylation was proposed as the major pathway for hydralazine clearance, where the acetylated drug, 3-methyl-s-triazolo[3,4-a )phthalazine (ITI), may be further metabolized to 3-hydroxymethyl-s -triazolo(3,4-a)phthalazine
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY